ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Rigel bags first FDA approval
July 16, 2018Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment. -
Rigel Pharma Awaits FDA Approval for Tavalisse, Builds Commercial Org for Drug Launch
January 16, 2018As the company is awaiting the regulatory approval of a rare blood disease drug and has built an internal infrastructure to commercialize the product -
Rigel submits new drug application to FDA for Fostamatinib in Chronic ITP
April 19, 2017Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for fostamatinib in patients with chronic and persistent immune thrombocytopenia (ITP).
Pharma Sources Insight January 2025
